Notice: This company has been marked as potentially delisted and may not be actively trading. TF Financial (THRD) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends THRD vs. IRON, AMPH, BLTE, HRMY, GPCR, GLPG, MNKD, XNCR, DVAX, and INDVShould you be buying TF Financial stock or one of its competitors? The main competitors of TF Financial include Disc Medicine (IRON), Amphastar Pharmaceuticals (AMPH), Belite Bio (BLTE), Harmony Biosciences (HRMY), Structure Therapeutics (GPCR), Galapagos (GLPG), MannKind (MNKD), Xencor (XNCR), Dynavax Technologies (DVAX), and Indivior (INDV). These companies are all part of the "pharmaceutical preparations" industry. TF Financial vs. Disc Medicine Amphastar Pharmaceuticals Belite Bio Harmony Biosciences Structure Therapeutics Galapagos MannKind Xencor Dynavax Technologies Indivior Disc Medicine (NASDAQ:IRON) and TF Financial (NASDAQ:THRD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, community ranking and risk. Which has preferable valuation and earnings, IRON or THRD? TF Financial is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDisc MedicineN/AN/A-$76.43M-$3.98-16.21TF FinancialN/AN/A-$30.82M-$0.62-17.48 Does the MarketBeat Community favor IRON or THRD? TF Financial received 12 more outperform votes than Disc Medicine when rated by MarketBeat users. However, 84.48% of users gave Disc Medicine an outperform vote while only 67.78% of users gave TF Financial an outperform vote. CompanyUnderperformOutperformDisc MedicineOutperform Votes4984.48% Underperform Votes915.52%TF FinancialOutperform Votes6167.78% Underperform Votes2932.22% Which has more volatility and risk, IRON or THRD? Disc Medicine has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, TF Financial has a beta of 2.64, suggesting that its stock price is 164% more volatile than the S&P 500. Do analysts recommend IRON or THRD? Disc Medicine presently has a consensus price target of $87.50, suggesting a potential upside of 35.66%. TF Financial has a consensus price target of $20.33, suggesting a potential upside of 87.58%. Given TF Financial's higher probable upside, analysts clearly believe TF Financial is more favorable than Disc Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10TF Financial 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is IRON or THRD more profitable? TF Financial's return on equity of -9.31% beat Disc Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Disc MedicineN/A -25.24% -23.96% TF Financial N/A -9.31%-9.03% Does the media refer more to IRON or THRD? In the previous week, Disc Medicine had 6 more articles in the media than TF Financial. MarketBeat recorded 6 mentions for Disc Medicine and 0 mentions for TF Financial. Disc Medicine's average media sentiment score of 0.86 beat TF Financial's score of 0.00 indicating that Disc Medicine is being referred to more favorably in the media. Company Overall Sentiment Disc Medicine Positive TF Financial Neutral Do insiders and institutionals have more ownership in IRON or THRD? 83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 94.0% of TF Financial shares are owned by institutional investors. 4.2% of Disc Medicine shares are owned by insiders. Comparatively, 5.9% of TF Financial shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryTF Financial beats Disc Medicine on 9 of the 16 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get TF Financial News Delivered to You Automatically Sign up to receive the latest news and ratings for THRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THRD vs. The Competition Export to ExcelMetricTF FinancialPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$488.45M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-17.4810.5589.7417.16Price / SalesN/A196.061,117.09117.04Price / CashN/A57.1643.1037.86Price / Book1.635.094.784.78Net Income-$30.82M$151.83M$120.31M$225.60M TF Financial Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THRDTF Financial1.3423 of 5 stars$10.84-0.4%$20.33+87.6%-3.9%$488.45MN/A-17.48N/AGap DownIRONDisc Medicine3.4713 of 5 stars$66.18+2.0%$87.50+32.2%+10.7%$1.97BN/A-16.3078Insider TradeAMPHAmphastar Pharmaceuticals4.8626 of 5 stars$40.84-3.3%$60.33+47.7%-34.7%$1.96B$644.40M14.081,761BLTEBelite Bio2.0985 of 5 stars$63.10+1.2%$89.00+41.0%+43.1%$1.93BN/A-56.1620HRMYHarmony Biosciences4.7827 of 5 stars$33.06+2.1%$47.00+42.2%+6.2%$1.89B$681.88M15.59200Analyst ForecastAnalyst RevisionGPCRStructure Therapeutics2.3713 of 5 stars$31.00-0.8%$85.67+176.3%-15.5%$1.78BN/A-42.23136Analyst ForecastNews CoverageGap UpGLPGGalapagos0.617 of 5 stars$26.91+0.3%$30.75+14.3%-31.8%$1.77B$260.09M0.001,123MNKDMannKind3.1849 of 5 stars$6.27-4.1%$8.67+38.2%+100.3%$1.73B$267.20M89.29400Analyst UpgradeAnalyst RevisionNews CoverageXNCRXencor4.3207 of 5 stars$24.52+2.0%$36.56+49.1%+18.1%$1.72B$168.34M-7.51280DVAXDynavax Technologies4.6668 of 5 stars$12.85-0.8%$22.00+71.2%-6.6%$1.69B$260.81M100.00408News CoveragePositive NewsINDVIndivior2.456 of 5 stars$12.08+4.4%$16.00+32.5%-25.7%$1.67B$1.18B-294.251,164Positive News Related Companies and Tools Related Companies Disc Medicine Competitors Amphastar Pharmaceuticals Competitors Belite Bio Competitors Harmony Biosciences Competitors Structure Therapeutics Competitors Galapagos Competitors MannKind Competitors Xencor Competitors Dynavax Technologies Competitors Indivior Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:THRD) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TF Financial Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share TF Financial With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free THRD Stock Alerts